Evidence map›Paper›PMID 31101593›Full record

ArticleEBioMedicine2019

Botao Fa, Chengwen Luo, Zhou Tang, Yuting Yan, Yue Zhang, Zhangsheng Yu

Abstract read
In one paragraph

Article in EBioMedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Botao FaDepartment of Bioinformatics and Biostatistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China; SJTU-Yale Joint Centre for Biostatistics, Shanghai Jiao Tong University, Shanghai, China.
Chengwen LuoDepartment of Bioinformatics and Biostatistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China; SJTU-Yale Joint Centre for Biostatistics, Shanghai Jiao Tong University, Shanghai, China.
Zhou TangSJTU-Yale Joint Centre for Biostatistics, Shanghai Jiao Tong University, Shanghai, China.
Yuting YanSJTU-Yale Joint Centre for Biostatistics, Shanghai Jiao Tong University, Shanghai, China.
Yue ZhangDepartment of Bioinformatics and Biostatistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China; SJTU-Yale Joint Centre for Biostatistics, Shanghai Jiao Tong University, Shanghai, China.
Zhangsheng YuDepartment of Bioinformatics and Biostatistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China; SJTU-Yale Joint Centre for Biostatistics, Shanghai Jiao Tong University, Shanghai, China. Electronic address: yuzhangsheng@sjtu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough many prognostic single-gene (SG) lists have been identified in cancer research, application of these features is hampered due to poor robustness and performance on independent datasets. Pathway-based approaches have thus emerged which embed biological knowledge to yield reproducible features.

methodsPathifier estimates pathways deregulation score (PDS) to represent the extent of pathway deregulation based on expression data, and most of its applications treat pathways as independent without addressing the effect of gene overlap between pathway pairs which we refer to as crosstalk. Here, we propose a novel procedure based on Pathifier methodology, which for the first time has been utilized with crosstalk accommodated to identify disease-specific features to predict prognosis in patients with hepatocellular carcinoma (HCC).

findingsWith the cohort (N = 355) of HCC patients from The Cancer Genome Atlas (TCGA), cross validation (CV) revealed that PDSs identified were more robust and accurate than the SG features by deep learning (DL)-based approach. When validated on external HCC datasets, these features outperformed the SGs consistently.

interpretationOn average, we provide 10.2% improvement of prediction accuracy. Importantly, governing genes in these features provide valuable insight into the cancer hallmarks of HCC. We develop an R package PATHcrosstalk (available from GitHub https://github.com/fabotao/PATHcrosstalk) with which users can discover pathways of interest with crosstalk effect considered.

Indexed as

Biomarkers, TumorSignal TransductionCarcinoma, HepatocellularComputational BiologyDatabases, GeneticGene Expression ProfilingGene Regulatory NetworksHumansLiver NeoplasmsPrognosisReproducibility of ResultsSurvival AnalysisBiomarkers, TumorBiomarkerCrosstalkDeep learningHepatocellular carcinomaOverall survivalPathway-based

Identifiers

PMID31101593
PMCPMC6606892

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.